Introduction: The current SARS-CoV-2 pandemic urgently demands for both prevention and treatment strategies. RNA-dependent RNA-polymerase (RdRp), which has no counterpart in human cells, is an excellent target for drug development. Given the time-consuming process of drug development, repurposing drugs approved for other indications or at least successfully tested in terms of safety and tolerability, is an attractive strategy to rapidly provide an effective medication for severe COVID-19 cases.Areas covered: The currently available data and upcominSg studies on RdRp which can be repurposed to halt SARS-CoV-2 replication, are reviewed.Expert opinion: Drug repurposing and design of novel compounds are proceeding in parallel to provide a quick response and new specific drugs, respectively. Notably, the proofreading SARS-CoV-2 exonuclease activity could limit the potential for drugs designed as immediate chain terminators and favor the development of compounds acting through delayed termination. While vaccination is awaited to curb the SARS-CoV-2 epidemic, even partially effective drugs from repurposing strategies can be of help to treat severe cases of disease. Considering the high conservation of RdRp among coronaviruses, an improved knowledge of its activity invitro can provide useful information for drug development or drug repurposing to combat SARS-CoV-2 as well as future pandemics.

Ilaria Vicenti

Maurizio Zazzi

Francesco Saladini

Expert Opinion on Therapeutic Patents

EXPERT OPINION ON THERAPEUTIC PATENTS (ISSN 1354-3776 [PRINT], 1744-7674 [ELECTRONIC]) 是 MEDLINE 索引、同行评审的国际期刊，发表关于近期药物专利权利要求的评论文章，为未来发展提供专家意见，在科学文献的背景下。编辑欢迎：评论涵盖最近关于具有治疗潜力的化合物或应用的专利权利要求，包括具有特定分子靶标的生物治疗药物和小分子药物；和特定治疗领域的专利申请趋势专利评估审查个别专利的目的和化学和生物权利要求与知识产权相关问题的观点观众包括制药行业的科学家、管理人员和决策者以及与研发密切相关的其他人，例如我们的生物科学期刊，在此处登录以开始访问，最新的两卷完整卷免费提供给您 14 天。

Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [PRINT], 1744-7674 [ELECTRONIC]) is an international peer-reviewed journal indexed in MEDLINE, focusing on commentaries regarding recent drug patent claims to provide expert insights for future developments. The editorial team welcomes reviews covering patent claims related to compounds or applications with therapeutic potential, including biotherapeutics and small molecules targeting specific molecular pathways, as well as trends in patent applications within specific therapeutic areas. The journal also evaluates the purposes of individual patents and discusses issues related to chemical and biological claims and intellectual property. The audience includes scientists, managers, and decision-makers in the pharmaceutical industry, as well as other professionals closely related to research and development. We offer free access to the latest two complete volumes for 14 days.

《Expert Opinion on Therapeutic Patents》（ISSN 1354-3776 [印刷版]，1744-7674 [电子版]）是一本国际同行评审的期刊，收录于MEDLINE，专注于近期药物专利的评论文章，旨在为未来的发展提供专家见解。编辑欢迎关于具有治疗潜力的化合物或应用的专利权利要求的评论，包括针对特定分子靶标的生物治疗药物和小分子药物，以及特定治疗领域的专利申请趋势。期刊还评估个别专利的目的，探讨与化学和生物权利要求及知识产权相关的问题。读者包括制药行业的科学家、管理人员和决策者，以及与研发密切相关的其他专业人士。我们提供最新的两卷完整卷，供您免费访问14天。

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

Considering the high conservation of RdRp among coronaviruses, an improved knowledge of its activity in vitro can provide useful information for drug development or drug repurposing to combat SARS-CoV-2 as well as future pandemics.

Category	Quartile
医学	2
医学, 药物化学	2
医学, 药学	2

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
PHARMACOLOGY & PHARMACY	1